Tavo Biotherapeutics

Tavo biotherapeutics email format

Verified email-pattern data for Tavo Biotherapeutics is currently limited. You can still use the company insights and contact sections below.
Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology. TAV-001 engages two novel targets that represent fundamental mechanisms underlying the pathology of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown signals of neuroprotection as well as substantial reduction in intraocular pressure, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic retinopathy, diabetic macular edema, and both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.

Company Details

Employees
9
Founded
-
Address
Critical Unmet Needs In Ophthalmology
Industry
Biotechnology Research
Keywords
OculoTherapy.
Looking for a particular Tavo Biotherapeutics employee's phone or email?

Tavo Biotherapeutics Questions

Top Tavo Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant